echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 78% objective remission rate: positive results of new therapy for intractable brain tumors in children

    78% objective remission rate: positive results of new therapy for intractable brain tumors in children

    • Last Update: 2019-10-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, y-mabs therapeutics company announced at the annual meeting of the international children's tumor Association (SIOP) that its humanized monoclonal antibody targeting gD2 antigen, naxitamab, combined with GM-CSF, has obtained positive efficacy and safety data in clinical trials for the treatment of neuroblastoma and osteosarcoma in children Neuroblastoma is one of the most common cancers in infants It is a very aggressive tumor, even with highly effective treatment, the survival rate of patients is still less than 50% Osteosarcoma is a common malignant bone tumor in children, which is common in the long bone Although the treatment of osteosarcoma has greatly improved in recent years, the improvement of survival time of patients is very limited Naxitamab is a humanized monoclonal antibody targeting gD2 antigen GD2 antigen is expressed on the surface of neuroectodermal tumors, including neuroblastoma, melanoma and osteosarcoma By combining with gD2 antigen on the surface of tumor, naxitamab can induce cytotoxic reaction of antibody vector and activate complement system in immune system, so as to achieve the effect of killing tumor It has been approved by FDA as an orphan drug for the treatment of neuroblastoma and osteosarcoma, and as a breakthrough therapy for the treatment of high-risk neuroblastoma in combination with GM-CSF Currently, the drug is used in clinical trials to treat recurrent / refractory high-risk neuroblastoma, osteosarcoma, and other gD2 positive tumors in children Action mechanism of naxitamab (photo source: y-mabs website) In the first group of children with neuroblastoma in the 1 / 2 phase clinical trial named 12-230, 28 high-risk relapse / refractory patients who were not suitable for induction chemotherapy received the combination treatment of nexitamab and GM-CSF, and more than half of them were also difficult to receive second-line chemotherapy The trial data showed that the combination therapy achieved 78% objective response rate (ORR) and 24 months PFS in 50% of patients In the second group of children with neuroblastoma in the 12-230 trial, 30 patients who received salvage therapy but had poor results received the combination treatment of nexitamab and GM-CSF, and one third of them had relapsed more than twice, and 89% of them had received anti gD2 drugs Experimental data show that the combination therapy can achieve 37% Orr and 36% PFS for 24 months, which brings significant clinical benefits to these refractory patients In a phase 2 trial, named 15-096, for children with recurrent osteosarcoma, the combination therapy showed good safety ▲ clinical research and development progress of naxitamab (photo source: y-mabs official website) "We are pleased to see excellent objective remission rates in patients in the 12-230 trial At the same time, we are also very satisfied with the duration of remission in patients, which is consistent with the results we observed in another international multicenter 201 trial, which are crucial for us to submit the application for approval of biological agents, "Claus, CEO of y-mabs Dr Moller said: "the data of the 201 trial shows that the overall remission rate of patients has exceeded 70%, and this data seems to be still growing, we believe that this will be a major good news for patients with neuroblastoma." reference material: [1] Y-mAbs Announces Naxitamab Update, Retrieved October 25, 2019, from https://www.globenewswire.com/news-release/2019/10/25/1935712/0/en/Y-mAbs-Announces-Naxitamab-Update.html A kind of
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.